Swiss precision oncology company Oncobit has announced the launch of Oncular™ in the United States in collaboration with TrilliumBiO.
Entering the US market represents a significant milestone for the company and demonstrates its ability to translate Swiss innovation into international growth. The launch will expand access to advanced monitoring solutions for patients with uveal melanoma and further strengthen Oncobit’s international presence.
Oncobit participated in the UpScaler programme, where founders and leadership teams prepare for growth challenges through peer exchange and workshops with experienced entrepreneurs and industry experts.
SwissEF and the UpScaler programme congratulate the entire Oncobit team on this important achievement and wish them continued success as they scale internationally.